See more : Transcendent Group AB (publ) (TRG.ST) Income Statement Analysis – Financial Results
Complete financial analysis of Sientra, Inc. (SIEN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sientra, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Marathon Group Corp. (PDPR) Income Statement Analysis – Financial Results
- Globe Commercials Limited (GLCL.BO) Income Statement Analysis – Financial Results
- Krsnaa Diagnostics Limited (KRSNAA.BO) Income Statement Analysis – Financial Results
- Waraba Gold Limited (WARAF) Income Statement Analysis – Financial Results
- Minster Financial Corp. (MTFC) Income Statement Analysis – Financial Results
Sientra, Inc. (SIEN)
About Sientra, Inc.
Sientra, Inc., a medical aesthetics company, develops and sells medical aesthetics products in the United States and internationally. It offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra Round, Sientra Teardrop, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names. The company also provides body contouring products; facial and nasal implants; saline filled sizers. It serves to hospitals, surgery centers, plastic surgeons, dermatologists and other specialties. The company was formerly known as Juliet Medical, Inc. and changed its name to Sientra, Inc. in April 2007. Sientra, Inc. was incorporated in 2003 and is headquartered in Santa Barbara, California.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 90.55M | 80.68M | 71.24M | 83.70M | 68.13M | 36.54M | 20.73M | 38.11M | 44.73M | 35.17M | 10.45M |
| Cost of Revenue | 48.96M | 36.35M | 32.30M | 33.01M | 26.82M | 14.17M | 6.88M | 10.65M | 11.50M | 8.59M | 2.35M |
| Gross Profit | 41.59M | 44.34M | 38.94M | 50.69M | 41.30M | 22.37M | 13.85M | 27.45M | 33.23M | 26.58M | 8.10M |
| Gross Profit Ratio | 45.94% | 54.95% | 54.66% | 60.56% | 60.63% | 61.22% | 66.82% | 72.04% | 74.29% | 75.57% | 77.49% |
| Research & Development | 14.06M | 10.46M | 10.31M | 13.54M | 10.95M | 9.81M | 9.70M | 7.20M | 4.71M | 4.48M | 3.67M |
| General & Administrative | 41.53M | 31.77M | 38.19M | 46.77M | 42.42M | 41.54M | 23.58M | 18.74M | 10.71M | 18.08M | 9.94M |
| Selling & Marketing | 55.05M | 48.46M | 52.55M | 80.19M | 67.72M | 33.91M | 20.61M | 25.76M | 23.60M | 22.23M | 17.92M |
| SG&A | 96.58M | 80.23M | 90.74M | 126.96M | 110.13M | 75.45M | 44.18M | 44.50M | 34.31M | 40.31M | 27.86M |
| Other Expenses | 12.00K | 6.56M | 111.00K | -55.00K | 39.00K | -95.00K | -36.00K | 360.00K | 2.15M | -46.00K | -1.00K |
| Operating Expenses | 110.64M | 90.69M | 101.06M | 140.50M | 121.08M | 85.26M | 53.89M | 51.70M | 39.02M | 44.79M | 31.53M |
| Cost & Expenses | 159.60M | 127.03M | 133.36M | 173.51M | 147.90M | 99.43M | 60.77M | 62.35M | 50.52M | 53.38M | 33.88M |
| Interest Income | 130.00K | 4.00K | 206.00K | 1.41M | 532.00K | 172.00K | 63.00K | 32.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 9.53M | 8.25M | 9.45M | 4.57M | 3.43M | 1.23M | 98.00K | 3.10M | 2.17M | 872.00K | 0.00 |
| Depreciation & Amortization | 6.78M | 10.93M | 4.41M | 9.05M | 3.32M | 3.03M | 1.18M | 318.00K | 275.00K | 280.00K | 288.00K |
| EBITDA | -62.27M | -46.35M | -70.31M | -103.57M | -75.88M | -59.78M | -38.48M | -38.53M | -3.64M | -17.97M | -23.15M |
| EBITDA Ratio | -68.77% | -43.91% | -81.00% | -96.49% | -111.38% | -163.59% | -192.95% | -62.60% | -8.13% | -51.10% | -221.55% |
| Operating Income | -69.05M | -46.35M | -62.12M | -89.81M | -79.77M | -62.89M | -40.03M | -38.53M | -5.79M | -18.21M | -23.43M |
| Operating Income Ratio | -76.26% | -57.45% | -87.19% | -107.30% | -117.10% | -172.10% | -193.08% | -101.10% | -12.93% | -51.77% | -224.29% |
| Total Other Income/Expenses | -4.23M | -16.15M | -4.96M | -16.97M | -2.86M | -1.16M | -71.00K | -2.71M | -26.00K | -918.00K | -1.00K |
| Income Before Tax | -73.69M | -62.50M | -89.91M | -106.78M | -82.63M | -64.05M | -40.11M | -41.23M | -5.81M | -19.13M | -23.43M |
| Income Before Tax Ratio | -81.38% | -77.46% | -126.21% | -127.58% | -121.29% | -175.26% | -193.43% | -108.20% | -12.99% | -54.38% | -224.30% |
| Income Tax Expense | 27.00K | 21.00K | 33.00K | 34.00K | -4.00K | -17.00K | 61.00K | 3.14M | 4.04M | 826.00K | -1.00K |
| Net Income | -73.72M | -62.52M | -89.95M | -106.82M | -82.63M | -64.03M | -40.17M | -41.23M | -5.81M | -19.13M | -23.43M |
| Net Income Ratio | -81.41% | -77.49% | -126.26% | -127.62% | -121.29% | -175.22% | -193.72% | -108.20% | -12.99% | -54.38% | -224.30% |
| EPS | -10.27 | -10.96 | -17.91 | -26.27 | -32.53 | -33.42 | -22.03 | -26.14 | -22.83 | -20.90 | -25.61 |
| EPS Diluted | -10.27 | -10.96 | -17.91 | -26.27 | -32.53 | -33.42 | -22.03 | -26.14 | -22.83 | -20.90 | -25.61 |
| Weighted Avg Shares Out | 7.17M | 5.71M | 5.02M | 4.07M | 2.54M | 1.92M | 1.82M | 1.58M | 254.54K | 915.12K | 915.12K |
| Weighted Avg Shares Out (Dil) | 7.18M | 5.71M | 5.02M | 4.07M | 2.54M | 1.92M | 1.82M | 1.58M | 254.54K | 915.12K | 915.12K |
7 Short-Squeeze Stocks to Buy Before They Soar
As much as we may recognize that short sellers perform a valuable service for the equities market, the concept of targeting short-squeeze stocks to buy just to penalize the pessimists carries cathartic value. Fundamentally, market bears operate like great white...
Sientra, Inc. (SIEN) Q3 2022 Earnings Call Transcript
Sientra, Inc. (NASDAQ:SIEN ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Oliver Bennett - SVP, General Counsel & Chief Compliance Officer Ron Menezes - President, CEO Lisa Rosas - SVP, Sales and Marketing Denise...
Sientra to Report Third Quarter 2022 Financial Results on November 10, 2022
SANTA BARBARA, Calif., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, today announced that it will release financial results for...
Sientra, Inc. (SIEN) CEO Ron Menezes on Q2 2022 Results - Earnings Call Transcript
Sientra, Inc. (NASDAQ:SIEN ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Oliver Bennett - Senior Vice President, General Counsel & Chief Compliance Officer Ron Menezes - President & Chief Executive Officer Andy Schmidt -...
7 Stocks Due for a Stunning Short Squeeze
Although the general rule of thumb is to avoid equities with heavy short interest, the new normal has brought with it new paradigms. One of these fresh approaches urges speculators to acquire short-squeeze stocks in an effort to move the...
Penny Stocks to Buy on August 8th? 3 to Watch
Here's what you need to know about buying penny stocks on August 8th The post Penny Stocks to Buy on August 8th? 3 to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Sientra To Participate At The 19th Annual Craig-Hallum Institutional Investor Conference
SANTA BARBARA, Calif., May 18, 2022 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), announced today its participation at the Virtual 19 th Annual Craig-Hallum Institutional Investor Conference, which takes place June 1 st , 2022.
Sientra, Inc. (SIEN) CEO Ron Menezes on Q1 2022 Results - Earnings Call Transcript
Sientra, Inc. (NASDAQ:SIEN ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Oliver Bennett - Senior Vice President, General Counsel & Chief Compliance Officer Ron Menezes - President & Chief Executive Officer Andy Schmidt -...
Sientra (SIEN) Reports Q1 Loss, Tops Revenue Estimates
Sientra (SIEN) delivered earnings and revenue surprises of -11.54% and 5.67%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Sientra to Report First Quarter 2022 Financial Results on May 12, 2022
SANTA BARBARA, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, today announced that it will release financial results for...
Source: https://incomestatements.info
Category: Stock Reports